Peel Hunt reaffirmed their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note issued to investors on Thursday. Peel Hunt currently has a GBX 1,390 ($19.52) price objective on the stock.

Several other equities research analysts also recently commented on HIK. JPMorgan Chase & Co. cut their target price on shares of Hikma Pharmaceuticals from GBX 1,500 ($21.06) to GBX 1,250 ($17.55) and set a neutral rating on the stock in a research report on Friday, October 6th. Jefferies Group reiterated a hold rating and set a GBX 1,045 ($14.67) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, November 9th. Numis Securities upgraded shares of Hikma Pharmaceuticals to a buy rating and set a GBX 1,300 ($18.26) target price on the stock in a research report on Thursday, November 9th. Stifel Nicolaus cut their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($18.54) to GBX 1,000 ($14.04) and set a hold rating on the stock in a research report on Thursday, November 9th. Finally, lowered their price target on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.89) to GBX 865 ($12.15) and set a reduce rating for the company in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 1,171 ($16.44).

Shares of Hikma Pharmaceuticals (LON:HIK) opened at GBX 942 ($13.23) on Thursday. Hikma Pharmaceuticals has a 1 year low of GBX 906.50 ($12.73) and a 1 year high of GBX 2,346 ($32.94). The company has a market cap of $2,270.00 and a P/E ratio of 1,962.50.

COPYRIGHT VIOLATION NOTICE: “Peel Hunt Reiterates Hold Rating for Hikma Pharmaceuticals (HIK)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/peel-hunt-reiterates-hold-rating-for-hikma-pharmaceuticals-hik/1843436.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.